Momenta Pharma is acquired by Johnson & Johnson and with it nipocalimab

Momenta Pharmaceuticals, Inc., a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases announced that it has entered into a definitive agreement for Johnson & Johnson to acquire Momenta for $52.50 per share in an all-cash transaction, implying a fully-diluted equity value of $6.5 billion. The agreement was unanimously approved by the Boards of Directors of both companies. Programs such as nipocalimab have the potential to improve the lives of countless patients suffering from autoimmune and fetal maternal diseases. The transaction is expected to close in the second half of 2020, pending the satisfaction of all conditions to the completion of the tender offer and merger. Until that time, Momenta will continue to operate as a separate and independent company.